These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 35238576)
1. Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy. Wu S; Huang Y; Wang T; Li K; Lu J; Huang M; Dong G; Sheng C J Med Chem; 2022 Mar; 65(6):4818-4831. PubMed ID: 35238576 [TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Structure-Activity relationships of Evodiamine-Based topoisomerase (Top)/Histone deacetylase (HDAC) dual inhibitors. Zhu F; Meng X; Liang H; Sheng C; Dong G; Liu D; Wu S Bioorg Chem; 2022 May; 122():105702. PubMed ID: 35286923 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. Cheng C; Yun F; He J; Ullah S; Yuan Q Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors. Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity. Liu M; Gao S; Liang T; Qiu X; Yang X; Fang H; Hou X J Med Chem; 2022 Sep; 65(18):12200-12218. PubMed ID: 36097406 [TBL] [Abstract][Full Text] [Related]
6. Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity. Huang Y; Chen S; Wu S; Dong G; Sheng C Acta Pharm Sin B; 2020 Jul; 10(7):1294-1308. PubMed ID: 32874829 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. Xie R; Li Y; Tang P; Yuan Q Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397 [TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer. Wan G; Feng Z; Zhang Q; Li X; Ran K; Feng H; Luo T; Zhou S; Su C; Wei W; Wang N; Gao C; Zhao L; Yu L J Med Chem; 2022 Dec; 65(24):16541-16569. PubMed ID: 36449947 [TBL] [Abstract][Full Text] [Related]
9. Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. Pan T; Dan Y; Guo D; Jiang J; Ran D; Zhang L; Tian B; Yuan J; Yu Y; Gan Z Eur J Med Chem; 2021 Nov; 224():113672. PubMed ID: 34237620 [TBL] [Abstract][Full Text] [Related]
10. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer. Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor. Duan W; Li J; Inks ES; Chou CJ; Jia Y; Chu X; Li X; Xu W; Zhang Y J Med Chem; 2015 May; 58(10):4325-38. PubMed ID: 25906087 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of novel HDAC inhibitors with a 3-(benzazol-2-yl)quinoxaline framework. Yang Y; Liu Q; Wang X; Gou S Bioorg Med Chem Lett; 2023 May; 88():129305. PubMed ID: 37116762 [TBL] [Abstract][Full Text] [Related]
13. Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency. Wang Y; Sun M; Wang Y; Qin J; Zhang Y; Pang Y; Yao Y; Yang H; Duan Y Eur J Med Chem; 2021 Dec; 225():113790. PubMed ID: 34454126 [TBL] [Abstract][Full Text] [Related]
14. β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies. Namballa HK; Anchi P; Lakshmi Manasa K; Soni JP; Godugu C; Shankaraiah N; Kamal A Bioorg Chem; 2021 Dec; 117():105461. PubMed ID: 34753060 [TBL] [Abstract][Full Text] [Related]
15. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I. Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421 [TBL] [Abstract][Full Text] [Related]
16. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity. Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors. Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton. Sun S; Zhao W; Li Y; Chi Z; Fang X; Wang Q; Han Z; Luan Y Bioorg Chem; 2021 Mar; 108():104652. PubMed ID: 33497873 [TBL] [Abstract][Full Text] [Related]
20. Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents. Zheng H; Dai Q; Yuan Z; Fan T; Zhang C; Liu Z; Chu B; Sun Q; Chen Y; Jiang Y Bioorg Med Chem; 2022 Jan; 53():116524. PubMed ID: 34847495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]